| Course | PA 533 Obstetrics & Gynecology |
|---|---|
| Week | 5 |
| Paper type | Maternal-fetal risk brief |
| Length | About 660 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | Master of Physician Assistant Studies (MPAS) |
| Updated | October 2026 |
Free sample paper for PA 533 Week 5
Maternal-Fetal Risk Brief on Sertraline: L.M.'s Wish to Stop at 6 Weeks Weighed Against Two Prior Depressive Episodes, Exposure Data Read by Trimester and a Recommendation to Continue at the Same Dose
Student Name
Chamberlain University
PA 533: Obstetrics & Gynecology
Instructor Name
Month Day, Year
Maternal-Fetal Risk Brief on Sertraline: L.M.'s Wish to Stop at 6 Weeks Weighed Against Two Prior Depressive Episodes, Exposure Data Read by Trimester and a Recommendation to Continue at the Same Dose
The Exposure, With Its Timing
L.M. has taken sertraline 100 mg daily for two years, started after postpartum depression following the first birth. At 6 weeks of the current pregnancy, L.M. asked whether to stop it "for the baby." Timing matters: at 6 weeks the heart and major organs are forming, so any effect on structure would come from exposure in the coming weeks; later in pregnancy, the main questions are newborn adaptation and the persistent pulmonary hypertension signal.
The Exposure Side, Argued
First-trimester exposure and heart defects: a cohort of nearly a million pregnancies in the US Medicaid population found no meaningful increase in cardiac malformations with antidepressant use in the first trimester after accounting for confounding factors (Huybrechts et al., 2014). Sertraline is among the most studied antidepressants in pregnancy.
Later exposure: in the last weeks before birth, the drug reaches the baby, and after delivery a minority of exposed newborns are fussy, feed poorly or breathe fast for a day or two while the drug clears; nurses watch for this rather than treat it. Studies have also linked late exposure to a slightly higher rate of high blood pressure in the newborn's lungs, though the condition stays uncommon even among exposed babies.
The Untreated Side, Argued Equally
L.M. has had two depressive episodes, one severe postpartum. Stopping an antidepressant in pregnancy is associated with relapse, and untreated depression carries its own risks: poor prenatal care, poor nutrition, substance use, preterm birth, low birth weight, postpartum depression and, at worst, suicide. The ACOG guideline on mental health in pregnancy recommends that decisions weigh the risks of untreated illness alongside the risks of medication, and supports continuing effective treatment when the benefits outweigh the risks (American College of Obstetricians and Gynecologists, 2023).
Studied, or Simply Unstudied
Sertraline has large observational data; the absence of signal is evidence, not merely a lack of study. Some newer antidepressants have far less data, and "no known harm" for them means unstudied. That difference is one reason not to switch L.M. to another drug now.
A Recommendation That Commits
Continue sertraline 100 mg daily throughout pregnancy. Do not switch. Do not taper. Monitor mood at each visit with a validated screening questionnaire. Plan for the newborn team to be aware of the exposure so that any adaptation signs are watched for in the first days.
Judgment, Not a Prescription
This is a recommendation for L.M., whose history of severe postpartum depression tips the balance. For someone with a single mild episode years ago, stable without symptoms, a supervised taper before pregnancy might be reasonable. The brief does not set a rule for everyone.
L.M.'s Decision
L.M. said that hearing both sides "made it feel less like I'm choosing between me and the baby." L.M. chose to continue, and the plan adds an early postpartum check, two weeks after birth, ahead of the usual six-week visit.
What Is Watched
At each visit: a depression screening questionnaire, sleep and appetite, and any thoughts of self-harm, asked directly. At birth: the newborn team is told of the exposure. After birth: sertraline continues during breastfeeding, since only small amounts pass into milk and it is among the preferred choices for nursing parents.
If L.M. Had Chosen to Stop
The plan would have been a slow taper over four weeks with closer follow-up, a written relapse plan and a low threshold to restart. The choice would have been respected and documented.
References
American College of Obstetricians and Gynecologists. (2023). Treatment and management of mental health conditions during pregnancy and postpartum (Clinical Practice Guideline No. 5). Obstetrics and Gynecology, 141(6), 1262-1288. https://doi.org/10.1097/AOG.0000000000005202
Huybrechts, K. F., Palmsten, K., Avorn, J., Cohen, L. S., Holmes, L. B., Franklin, J. M., Mogun, H., Levin, R., Kowal, M., Setoguchi, S., & Hernandez-Diaz, S. (2014). Antidepressant use in pregnancy and the risk of cardiac defects. New England Journal of Medicine, 370(25), 2397-2407. https://doi.org/10.1056/NEJMoa1312828
Reading the PA 533 Week 5 instructions
The fifth week asks for a brief weighing an exposure in pregnancy against the condition it treats. State the exposure with its timing, since when in pregnancy it falls often matters more than what it is. Argue the exposure side with evidence on structural and later effects. Then give the untreated condition the same treatment: what it does to the pregnant person and to the pregnancy. Distinguish a drug that has been studied and found reassuring from one that is simply unstudied. Make a recommendation that commits, and say why it fits this person. Present it as clinical judgment rather than a universal rule. Record the patient's decision and the monitoring plan, and what would have happened with the other choice. Cite the main studies and guideline.
How this PA 533 Week 5 example is built
The brief opens with L.M. taking sertraline 100 mg for two years after postpartum depression, asking at 6 weeks whether to stop, and explains why organ formation timing matters. The exposure side cites Huybrechts and colleagues' Medicaid cohort finding no meaningful cardiac signal and describes transient newborn effects and a small lung blood pressure signal with late exposure. The untreated side lists relapse, poor prenatal care, preterm birth and suicide risk, citing the 2023 ACOG guideline. A section contrasts sertraline's large dataset with newer, unstudied drugs. The recommendation continues sertraline without switching. A judgment section explains why a different history might allow a taper. L.M.'s choice is recorded, followed by monitoring through breastfeeding and the taper plan that would have applied.
PA 533 Week 5 rubric: what full points look like
Points for this brief follow balance. A brief that argues only the medication's risks, or only its benefits, loses the most because the week tests comparison. Timing must be stated and used, not just mentioned. Faculty give strong credit for treating untreated illness with the same rigor as the exposure. Distinguishing studied from unstudied drugs earns marks for accuracy. The recommendation must commit; hedged conclusions such as discuss with your provider are marked down. Framing it as judgment for this patient adds credit. Monitoring and the patient's own decision should be recorded. The main study and current guideline should be cited correctly.
Common PA 533 Week 5 mistakes, and how to avoid them
Medication-in-pregnancy briefs often slide into listing every possible risk of the drug while ignoring the illness. Send the exposure, its timing and the patient's history, and the brief written for you would argue both sides with the same rigor, place the exposure in time and distinguish studied from unstudied drugs. A committed recommendation fits your patient, framed as judgment rather than a rule, with monitoring and the patient's decision recorded. If your exposure is an anticonvulsant, an antihypertensive or a vaccine, the same structure applies. Confirm the safety data for your specific drug with a current reference before relying on it.
Get a PA-533 Week 5 example written to your instructions
Send the Week 5 case with the exposure or medication it names, and a custom brief is written to it and returned inside 24 to 48 hours. The first one is free. If your section supplies a briefing template or a page limit, include it and the example is built to that size.
More PA 533 papers and MPAS samples
- PA 533 Week 1: Prenatal Screening Claim Post
- PA 533 Week 2: Gestational Dating Exercise
- PA 533 Week 3: Physiologic Adaptation Write-Up
- PA 533 Week 4: Prenatal Visit Schedule Rationale
- PA 533 Week 6: Abnormal Bleeding Workup
- PA 533 Week 7: Contraceptive Comparison Table
- PA 533 Week 8: Well-woman Visit Outline
- PA 532 Week 5: Procedure Step Sequence
- PA 531 Week 5: Stabilization Sequence Write-Up
- PA 530 Week 5: Overuse Injury Analysis
- PA 528 Week 5: Seizure Semiology Write-Up
PA 533 Week 5 questions, answered
How do I handle an exposure with almost no evidence behind it?
Say that, and say it in those terms. An absence of studies is a fact about the literature rather than a fact about the drug, and briefs that blur the two lose in both directions. Describe what does exist, what kind of study produced it, and what a clinician is left deciding without. That paragraph is often the strongest one in the document.
Should the brief mention breastfeeding?
Where the case runs past delivery, yes, and as a separate question. What crosses into milk and what crosses the placenta are different problems with different evidence behind them, and treating the two as one throws away a point that was easy to hold. If your instructions stop at delivery, mark the boundary in a line and stay inside it.
Whose decision does the brief describe?
The clinician's reasoning, written for a reader who will go on to discuss it with the patient. Briefs that leave the patient out entirely read as pharmacology exercises, and briefs that write the whole conversation out have turned into something else. A line or two on what the person carrying the pregnancy would need to hear is usually the right amount.
Where can I find a free PA 533 Week 5 sample paper?
This page holds the full PA 533 Week 5 risk brief weighing sertraline against untreated depression and recommending continuation.
Why does the PA 533 Week 5 sample advise against switching drugs?
Sertraline has large reassuring datasets, while many newer antidepressants are simply unstudied in pregnancy, so switching would trade evidence for uncertainty.